Adagene Operating Income Over Time
| ADAG Stock | USD 3.26 0.12 3.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adagene Performance and Adagene Correlation. Can Biotechnology industry sustain growth momentum? Does Adagene have expansion opportunities? Factors like these will boost the valuation of Adagene. If investors know Adagene will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Adagene demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth (0.87) | Return On Assets | Return On Equity |
The market value of Adagene is measured differently than its book value, which is the value of Adagene that is recorded on the company's balance sheet. Investors also form their own opinion of Adagene's value that differs from its market value or its book value, called intrinsic value, which is Adagene's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Adagene's market value can be influenced by many factors that don't directly affect Adagene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Adagene's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adagene represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Adagene's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Adagene and related stocks such as XBiotech, CervoMed, and Gain Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBIT | (15.2 M) | (15.2 M) | (15.2 M) | (9.9 M) | (21.8 M) | (37.5 M) | (52.8 M) | (34.1 M) | (21 M) | (31.2 M) | (18.3 M) | (25.1 M) | (34.5 M) | (37.5 M) | (42.5 M) | (38.2 M) | (40.1 M) |
| CRVO | 613 K | (16.4 M) | (11.8 M) | (7.9 M) | (7.3 M) | (6.4 M) | (14.9 M) | (11.3 M) | (12 M) | (11.6 M) | (16 M) | (24.7 M) | (16 M) | (7.8 M) | (18.2 M) | (16.4 M) | (15.6 M) |
| GANX | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (2.1 M) | (3.5 M) | (13.8 M) | (17.8 M) | (22.3 M) | (20.4 M) | (18.3 M) | (19.2 M) |
| NTRB | (400) | (400) | (400) | (400) | (400) | (400) | (151.3 K) | (171.9 K) | (3.3 M) | (2 M) | (2.6 M) | (3.9 M) | (4.1 M) | (4.9 M) | (6.7 M) | (6 M) | (5.7 M) |
| ACET | 21.4 M | 16.6 M | 25.4 M | 34.4 M | 34.4 M | 44.3 M | (1000) | (18.9 M) | (15 M) | (31.4 M) | (39.2 M) | (61.4 M) | (72.6 M) | (152 M) | (127.6 M) | (114.9 M) | (109.1 M) |
| FBIO | (3.2 M) | (35 M) | (27.2 M) | (35.8 M) | (20.7 M) | (50.5 M) | (65.7 M) | (89.8 M) | (120 M) | (110.8 M) | (94.3 M) | (188.5 M) | (203.6 M) | (142.3 M) | (110.4 M) | (99.3 M) | (104.3 M) |
| LITS | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (75.5 M) | (36.8 M) | 14.5 M | (17.5 M) | (20.1 M) | (21.1 M) |
| TCRX | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (26.2 M) | (48.6 M) | (66.6 M) | (93.5 M) | (134.8 M) | (121.3 M) | (115.3 M) |
| OSTX | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (4.8 M) | (4.4 M) | (4.3 M) | (6.8 M) | (6.1 M) | (6.4 M) |
| NRXP | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (1 M) | (713.2 K) | (22.1 M) | (95.2 M) | (44.3 M) | (27.6 M) | (19.7 M) | (17.7 M) | (18.6 M) |
Adagene and related stocks such as XBiotech, CervoMed, and Gain Therapeutics Operating Income description
Operating Income is the amount of profit realized from Adagene operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Adagene is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Adagene | ADAG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Building C14, Suzhou, |
| Exchange | NASDAQ Exchange |
USD 3.26
Check out Adagene Performance and Adagene Correlation. For more detail on how to invest in Adagene Stock please use our How to Invest in Adagene guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Adagene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.